Identification

Name
Fluvoxamine
Accession Number
DB00176  (APRD00425)
Type
Small Molecule
Groups
Approved, Investigational
Description

Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.

Structure
Thumb
Synonyms
  • Fluvoxamina
  • Fluvoxamine
  • Fluvoxaminum
External IDs
N06AB08
Product Ingredients
IngredientUNIICASInChI Key
Fluvoxamine maleate5LGN83G74V61718-82-9LFMYNZPAVPMEGP-PIDGMYBPSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act FluvoxamineTablet100 mgOralActavis Pharma Company2004-08-13Not applicableCanada
Act FluvoxamineTablet50 mgOralActavis Pharma Company2004-08-13Not applicableCanada
Ava-fluvoxamineTablet100 mgOralAvanstra Inc2011-08-222014-08-21Canada
Ava-fluvoxamineTablet50 mgOralAvanstra Inc2011-08-222014-08-21Canada
Bci Fluvoxamine TabletsTablet100.0 mgOralBaker Cummins Inc2005-07-042006-10-03Canada
Bci Fluvoxamine TabletsTablet50.0 mgOralBaker Cummins Inc2005-07-042006-10-03Canada
Dom-fluvoxamineTablet50 mgOralDominion Pharmacal2000-02-232016-10-25Canada
Dom-fluvoxamineTablet100 mgOralDominion Pharmacal2000-02-232016-10-25Canada
Fluvoxamine MaleateTablet, coated25 mg/1OralANI Pharmaceuticals, Inc.2011-08-09Not applicableUs62559 0158 01 nlmimage10 313b98dc
Fluvoxamine MaleateTablet, coated50 mg/1OralAidarex Pharmaceuticals LLC2011-08-09Not applicableUs62559 0159 01 nlmimage10 d13b68ab
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fluvoxamine TabletsTablet100 mgOralApotex Corporation1998-05-20Not applicableCanada
Apo-fluvoxamine TabletsTablet50 mgOralApotex Corporation1997-05-20Not applicableCanada
Fluvoxamine MaleateTablet, film coated25 mg/1OralMylan Pharmaceuticals2000-12-20Not applicableUs
Fluvoxamine MaleateTablet, film coated50 mg/1OralEon Labs, Inc.2000-11-29Not applicableUs
Fluvoxamine MaleateTablet100 mg/1OralGolden State Medical Supply2001-05-072017-10-26Us
Fluvoxamine MaleateTablet50 mg/1OralAmerincan Health Packaging2014-09-292017-10-31Us
Fluvoxamine MaleateTablet, film coated100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-03-12Not applicableUs
Fluvoxamine MaleateCapsule, extended release150 mg/1OralActavis Pharma Company2014-08-05Not applicableUs
Fluvoxamine MaleateTablet25 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2006-02-23Not applicableUs
Fluvoxamine MaleateTablet25 mg/1OralGolden State Medical Supply2001-05-072017-10-26Us
International/Other Brands
Dumirox (Abbott) / Faverin (Abbott) / Fevarin (Abbott) / Floxyfral (Abbott) / Maveral (Abbott)
Categories
UNII
O4L1XPO44W
CAS number
54739-18-3
Weight
Average: 318.3346
Monoisotopic: 318.155512541
Chemical Formula
C15H21F3N2O2
InChI Key
CJOFXWAVKWHTFT-XSFVSMFZSA-N
InChI
InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+
IUPAC Name
(2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine
SMILES
COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F

Pharmacology

Indication

For management of depression and for Obsessive Compulsive Disorder (OCD). Has also been used in the management of bulimia nervosa.

Structured Indications
Pharmacodynamics

Fluvoxamine, an aralkylketone-derivative agent, is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) that differs structurally from other SSRIs. It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of Fluvoxamine are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that Fluvoxamine is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Fluvoxamine has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of Fluvoxamine was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Fluvoxamine does not inhibit monoamine oxidase.

Mechanism of action

The exact mechanism of action of fluvoxamine has not been fully determined, but appears to be linked to its inhibition of CNS neuronal uptake of serotonin. Fluvoxamine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. In-vitro studies suggest that fluvoxamine is more potent than clomipramine, fluoxetine, and desipramine as a serotonin-reuptake inhibitor. Studies have also demonstrated that fluvoxamine has virtually no affinity for α1- or α2-adrenergic, β-adrenergic, muscarinic, dopamine D2, histamine H1, GABA-benzodiazepine, opiate, 5-HT1, or 5-HT2 receptors.

TargetActionsOrganism
ASodium-dependent serotonin transporter
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 2Not AvailableHuman
Absorption

Well absorbed, bioavailability of fluvoxamine maleate is 53%.

Volume of distribution
  • 25 L/kg
Protein binding

~77-80% (plasma protein)

Metabolism

Hepatic

Route of elimination

The main human metabolite was fluvoxamine acid which, together with its N-acetylated analog, accounted for about 60% of the urinary excretion products. Approximately 2% of fluvoxamine was excreted in urine unchanged. Following a 14C-labelled oral dose of fluvoxamine maleate (5 mg), an average of 94% of drug-related products was recovered in the urine within 71 hours.

Half life

15.6 hours

Clearance
Not Available
Toxicity

Side effects include anorexia, constipation, dry mouth, headache, nausea, nervousness, skin rash, sleep problems, somnolence, liver toxicity, mania, increase urination, seizures, sweating increase, tremors, or Tourette's syndrome.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not Available2549delAEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableA alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*3Not AvailableG alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.Details
Cytochrome P450 2D6CYP2D6*4Not Available3877G>AEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.Details

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Fluvoxamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Fluvoxamine.Experimental
AbirateroneThe serum concentration of Fluvoxamine can be increased when it is combined with Abiraterone.Approved
AcarboseFluvoxamine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Fluvoxamine.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Fluvoxamine.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Fluvoxamine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fluvoxamine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Fluvoxamine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Fluvoxamine.Approved
Acetylsalicylic acidFluvoxamine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Fluvoxamine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Fluvoxamine.Approved
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Fluvoxamine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Fluvoxamine.Approved, Investigational
AlaproclateFluvoxamine may increase the serotonergic activities of Alaproclate.Experimental
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Fluvoxamine.Approved, Vet Approved
AlbiglutideFluvoxamine may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Fluvoxamine.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Fluvoxamine.Experimental, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Alfaxalone.Vet Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Fluvoxamine.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Fluvoxamine.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Fluvoxamine.Approved, Vet Approved
AliskirenThe metabolism of Aliskiren can be decreased when combined with Fluvoxamine.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Fluvoxamine.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Allopregnanolone.Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Fluvoxamine.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Fluvoxamine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Fluvoxamine.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Fluvoxamine.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Alphaprodine.Illicit
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Fluvoxamine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Fluvoxamine.Approved, Withdrawn
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Fluvoxamine.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Fluvoxamine.Approved, Investigational
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Fluvoxamine.Experimental, Investigational
AmineptineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amineptine.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Fluvoxamine.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Fluvoxamine.Approved
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Fluvoxamine.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amitriptyline.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Fluvoxamine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluvoxamine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amoxapine.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Fluvoxamine.Approved, Vet Approved
AmperozideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Fluvoxamine.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Fluvoxamine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Fluvoxamine.Approved
AnagrelideThe metabolism of Anagrelide can be decreased when combined with Fluvoxamine.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Fluvoxamine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Fluvoxamine.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Fluvoxamine.Approved, Investigational
AprepitantThe metabolism of Aprepitant can be decreased when combined with Fluvoxamine.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Fluvoxamine.Approved
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Fluvoxamine.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Fluvoxamine.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Fluvoxamine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Fluvoxamine.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Fluvoxamine.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Fluvoxamine.Approved
ArticaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Articaine.Approved
AsenapineThe serum concentration of Asenapine can be increased when it is combined with Fluvoxamine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Fluvoxamine.Approved, Withdrawn
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Fluvoxamine.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Fluvoxamine.Approved
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Fluvoxamine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Atorvastatin.Approved
AV650The metabolism of AV650 can be decreased when combined with Fluvoxamine.Approved, Investigational
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Fluvoxamine.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Fluvoxamine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Azaperone.Investigational, Vet Approved
AzelastineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Fluvoxamine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Baclofen.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Fluvoxamine.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Barbital.Illicit
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Fluvoxamine.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Fluvoxamine.Approved, Investigational
BendamustineThe serum concentration of Bendamustine can be increased when it is combined with Fluvoxamine.Approved, Investigational
BendroflumethiazideFluvoxamine may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Fluvoxamine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Fluvoxamine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Benzocaine.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Fluvoxamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Fluvoxamine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Fluvoxamine.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Fluvoxamine.Approved, Vet Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Fluvoxamine.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Fluvoxamine.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Fluvoxamine.Approved
BezitramideBezitramide may increase the serotonergic activities of Fluvoxamine.Experimental, Illicit, Withdrawn
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Fluvoxamine.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Bifeprunox.Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Fluvoxamine.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Fluvoxamine.Investigational
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Fluvoxamine.Approved, Withdrawn
BortezomibThe metabolism of Bortezomib can be decreased when combined with Fluvoxamine.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Fluvoxamine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fluvoxamine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluvoxamine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Fluvoxamine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Fluvoxamine.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Fluvoxamine.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Brofaromine.Experimental
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Fluvoxamine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Fluvoxamine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Brotizolam.Approved, Investigational, Withdrawn
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Fluvoxamine.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Fluvoxamine.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Fluvoxamine.Approved, Investigational
BuprenorphineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Fluvoxamine.Approved
BuspironeBuspirone may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Fluvoxamine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluvoxamine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Butamben.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluvoxamine.Approved, Illicit, Vet Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Fluvoxamine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cabergoline.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Fluvoxamine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Fluvoxamine.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Fluvoxamine.Approved, Nutraceutical
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Fluvoxamine.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Fluvoxamine.Approved
Candesartan cilexetilThe metabolism of Candesartan can be decreased when combined with Fluvoxamine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Canertinib.Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Fluvoxamine.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Fluvoxamine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Fluvoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Fluvoxamine.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Fluvoxamine.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Fluvoxamine.Approved
CarmustineThe metabolism of Carmustine can be decreased when combined with Fluvoxamine.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Fluvoxamine.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Fluvoxamine.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Fluvoxamine.Approved, Investigational
CelecoxibFluvoxamine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Fluvoxamine.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Fluvoxamine.Approved, Vet Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Fluvoxamine.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Fluvoxamine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Fluvoxamine.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Fluvoxamine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Fluvoxamine.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Fluvoxamine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Fluvoxamine.Approved, Vet Approved
ChlorothiazideFluvoxamine may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Fluvoxamine.Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Fluvoxamine.Experimental
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Fluvoxamine.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Fluvoxamine.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneFluvoxamine may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Fluvoxamine.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Fluvoxamine.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Fluvoxamine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Fluvoxamine.Approved
CimetidineThe metabolism of Fluvoxamine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Fluvoxamine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Fluvoxamine.Approved, Investigational
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Fluvoxamine.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Fluvoxamine.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Fluvoxamine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Fluvoxamine.Approved
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Fluvoxamine.Approved
ClemastineThe metabolism of Fluvoxamine can be decreased when combined with Clemastine.Approved
ClenbuterolThe metabolism of Clenbuterol can be decreased when combined with Fluvoxamine.Approved, Investigational, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Fluvoxamine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clidinium.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Fluvoxamine.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Fluvoxamine.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Fluvoxamine.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Fluvoxamine.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Fluvoxamine.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Fluvoxamine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Fluvoxamine.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Fluvoxamine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clopenthixol.Experimental
ClopidogrelThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Fluvoxamine.Approved, Illicit
ClorindioneFluvoxamine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clothiapine.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Fluvoxamine.Approved, Illicit
ClotrimazoleThe metabolism of Fluvoxamine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Fluvoxamine.Approved
CobicistatThe serum concentration of Fluvoxamine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Fluvoxamine.Approved
CocaineThe metabolism of Fluvoxamine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Fluvoxamine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Fluvoxamine.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Fluvoxamine.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Fluvoxamine.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Fluvoxamine.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Fluvoxamine.Approved
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Fluvoxamine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cyclobenzaprine.Approved
CyclopenthiazideFluvoxamine may increase the hyponatremic activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Fluvoxamine.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Fluvoxamine.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Fluvoxamine can be decreased when used in combination with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Fluvoxamine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Fluvoxamine.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluvoxamine.Approved
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Fluvoxamine.Approved
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Fluvoxamine.Approved, Investigational
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Fluvoxamine.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Fluvoxamine.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Fluvoxamine.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Fluvoxamine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dapiprazole.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Fluvoxamine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Fluvoxamine.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Fluvoxamine.Approved, Investigational
DarunavirThe serum concentration of Fluvoxamine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Fluvoxamine.Approved
DasatinibThe metabolism of Dasatinib can be decreased when combined with Fluvoxamine.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Fluvoxamine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Fluvoxamine.Approved, Investigational
DeferasiroxThe serum concentration of Fluvoxamine can be increased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Fluvoxamine.Approved
DelavirdineThe metabolism of Fluvoxamine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fluvoxamine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Detomidine.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Fluvoxamine.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Fluvoxamine.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dexbrompheniramine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Fluvoxamine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Fluvoxamine.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Fluvoxamine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Fluvoxamine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Fluvoxamine.Approved, Illicit
DextromethorphanFluvoxamine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Fluvoxamine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dezocine.Approved, Investigational
DiazepamThe metabolism of Diazepam can be decreased when combined with Fluvoxamine.Approved, Illicit, Vet Approved
DibenzepinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dibenzepin.Experimental
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Fluvoxamine.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Fluvoxamine.Approved
DienogestThe metabolism of Dienogest can be decreased when combined with Fluvoxamine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Diethyl ether.Experimental
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fluvoxamine.Approved, Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Difenoxin.Approved, Illicit
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Fluvoxamine.Approved, Investigational
DigoxinThe metabolism of Digoxin can be decreased when combined with Fluvoxamine.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Fluvoxamine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Fluvoxamine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Fluvoxamine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Fluvoxamine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Fluvoxamine.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Fluvoxamine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dimenhydrinate.Approved
DinoprostoneThe metabolism of Dinoprostone can be decreased when combined with Fluvoxamine.Approved
DiphenadioneFluvoxamine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Fluvoxamine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluvoxamine.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Fluvoxamine.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Fluvoxamine.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Fluvoxamine.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dixyrazine.Experimental
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Fluvoxamine.Approved, Investigational
DoconexentThe metabolism of Doconexent can be decreased when combined with Fluvoxamine.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Fluvoxamine.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Fluvoxamine.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Fluvoxamine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Fluvoxamine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Fluvoxamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Doramectin.Vet Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Fluvoxamine.Approved
DosulepinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Fluvoxamine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Fluvoxamine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Fluvoxamine.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Illicit
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Fluvoxamine.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Drotebanol.Experimental, Illicit
DulaglutideFluvoxamine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Fluvoxamine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Fluvoxamine.Approved, Investigational
DyclonineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dyclonine.Approved
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Fluvoxamine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Fluvoxamine.Approved
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Fluvoxamine.Approved, Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Fluvoxamine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Fluvoxamine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Fluvoxamine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Eltanolone.Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Fluvoxamine.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Fluvoxamine.Approved
EmpagliflozinFluvoxamine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Fluvoxamine.Approved, Vet Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Fluvoxamine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Fluvoxamine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Fluvoxamine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Enflurane.Approved, Investigational, Vet Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Fluvoxamine.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Entacapone.Approved, Investigational
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Fluvoxamine.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Fluvoxamine.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Fluvoxamine.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Fluvoxamine.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Fluvoxamine.Approved, Nutraceutical
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ergonovine.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Fluvoxamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Fluvoxamine.Approved, Investigational
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Fluvoxamine.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Fluvoxamine.Approved, Investigational
EsmirtazapineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Esmirtazapine.Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Fluvoxamine.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Fluvoxamine.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Fluvoxamine.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Fluvoxamine.Approved, Investigational
EstramustineThe metabolism of Estramustine can be decreased when combined with Fluvoxamine.Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Fluvoxamine.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Fluvoxamine.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Fluvoxamine.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Fluvoxamine.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Fluvoxamine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Fluvoxamine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Fluvoxamine.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Fluvoxamine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ethotoin.Approved
Ethyl biscoumacetateFluvoxamine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Fluvoxamine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Fluvoxamine.Approved
EtodolacFluvoxamine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Etomidate.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Fluvoxamine.Approved, Investigational
EtoperidoneEtoperidone may increase the serotonergic activities of Fluvoxamine.Withdrawn
EtoposideThe metabolism of Etoposide can be decreased when combined with Fluvoxamine.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Fluvoxamine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Etravirine can be decreased when combined with Fluvoxamine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Fluvoxamine.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Fluvoxamine.Approved, Investigational
ExenatideFluvoxamine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Fluvoxamine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ezogabine.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Fluvoxamine.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Fluvoxamine.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Fluvoxamine.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineFluvoxamine may increase the serotonergic activities of Fenfluramine.Illicit, Investigational, Withdrawn
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Fluvoxamine.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Fluvoxamine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluvoxamine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Fluvoxamine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Fluvoxamine.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Fluvoxamine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Fluvoxamine.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Fluvoxamine.Approved, Withdrawn
FluanisoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fludiazepam.Approved, Illicit
FluindioneFluvoxamine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Fluvoxamine.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Fluvoxamine.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Fluvoxamine.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Fluvoxamine.Approved
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Fluvoxamine.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Fluvoxamine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluvoxamine.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Fluvoxamine.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Fluvoxamine.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Fluvoxamine.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fluspirilene.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Fluvoxamine.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Fluvoxamine.Approved
Fluticasone propionateThe metabolism of Fluticasone propionate can be decreased when combined with Fluvoxamine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Fluvoxamine.Approved
FormoterolThe metabolism of Formoterol can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Fluvoxamine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Fluvoxamine.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Fluvoxamine.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Fluvoxamine.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Fluvoxamine.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluvoxamine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Gabapentin Enacarbil.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Fluvoxamine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fluvoxamine.Approved, Illicit, Investigational
GavestinelThe metabolism of Gavestinel can be decreased when combined with Fluvoxamine.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Fluvoxamine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Fluvoxamine.Approved
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Fluvoxamine.Approved
GenisteinThe metabolism of Genistein can be decreased when combined with Fluvoxamine.Investigational
GepironeThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Gepirone.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Fluvoxamine.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Fluvoxamine.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Fluvoxamine.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Fluvoxamine.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Fluvoxamine.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Glutethimide.Approved, Illicit
GlyburideThe metabolism of Glyburide can be decreased when combined with Fluvoxamine.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Fluvoxamine.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Fluvoxamine.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Fluvoxamine.Investigational, Withdrawn
GuanabenzThe metabolism of Guanabenz can be decreased when combined with Fluvoxamine.Approved, Investigational
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Fluvoxamine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Fluvoxamine.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Fluvoxamine.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Fluvoxamine.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Heroin.Approved, Illicit, Investigational
HesperetinThe metabolism of Hesperetin can be decreased when combined with Fluvoxamine.Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Fluvoxamine.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Fluvoxamine.Approved, Investigational
HydracarbazineHydracarbazine may increase the serotonergic activities of Fluvoxamine.Experimental
HydrochlorothiazideFluvoxamine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Fluvoxamine.Approved, Vet Approved
HydroflumethiazideFluvoxamine may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Fluvoxamine.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Fluvoxamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Fluvoxamine.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Fluvoxamine.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Fluvoxamine.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Fluvoxamine.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Fluvoxamine.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Fluvoxamine resulting in a loss in efficacy.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Fluvoxamine.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Fluvoxamine.Approved
ImidafenacinThe metabolism of Imidafenacin can be decreased when combined with Fluvoxamine.Approved, Investigational
ImipramineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Imipramine.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Fluvoxamine.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Fluvoxamine.Approved
IndalpineIndalpine may increase the serotonergic activities of Fluvoxamine.Investigational, Withdrawn
IndapamideThe metabolism of Indapamide can be decreased when combined with Fluvoxamine.Approved
IndinavirThe metabolism of Indinavir can be decreased when combined with Fluvoxamine.Approved
IndiplonThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Indiplon.Investigational
indisulamThe metabolism of indisulam can be decreased when combined with Fluvoxamine.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Fluvoxamine.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Fluvoxamine.Approved
Insulin AspartFluvoxamine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirFluvoxamine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineFluvoxamine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineFluvoxamine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanFluvoxamine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproFluvoxamine may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Fluvoxamine.Approved, Investigational
Ioflupane I-123Fluvoxamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Fluvoxamine.Approved
IprindoleThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Iprindole.Experimental
IproclozideIproclozide may increase the serotonergic activities of Fluvoxamine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Fluvoxamine.Withdrawn
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Fluvoxamine.Approved, Investigational
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Fluvoxamine.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Fluvoxamine.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fluvoxamine.Approved, Vet Approved
IsoniazidThe metabolism of Fluvoxamine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Fluvoxamine.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Fluvoxamine.Approved
IsradipineThe metabolism of Isradipine can be decreased when combined with Fluvoxamine.Approved
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Fluvoxamine.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Fluvoxamine.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Fluvoxamine.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Fluvoxamine.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Fluvoxamine.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Fluvoxamine.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Fluvoxamine.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Fluvoxamine.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Fluvoxamine.Approved, Investigational
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Fluvoxamine.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Fluvoxamine.Approved, Vet Approved
L-TryptophanL-Tryptophan may increase the serotonergic activities of Fluvoxamine.Approved, Nutraceutical, Withdrawn
LabetalolThe metabolism of Labetalol can be decreased when combined with Fluvoxamine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Fluvoxamine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Fluvoxamine.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Fluvoxamine.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Fluvoxamine.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Fluvoxamine.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Fluvoxamine.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Fluvoxamine.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Fluvoxamine.Approved
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Fluvoxamine.Approved
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Fluvoxamine.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Fluvoxamine.Approved
LetrozoleThe metabolism of Letrozole can be decreased when combined with Fluvoxamine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Fluvoxamine.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Fluvoxamine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Levocabastine.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Fluvoxamine.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Fluvoxamine.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Fluvoxamine.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Fluvoxamine.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Fluvoxamine.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Fluvoxamine.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fluvoxamine.Approved
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Fluvoxamine.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Fluvoxamine.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Fluvoxamine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Fluvoxamine.Approved
LinezolidLinezolid may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluvoxamine.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Fluvoxamine.Approved
LiraglutideFluvoxamine may increase the hypoglycemic activities of Liraglutide.Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Fluvoxamine.Approved, Investigational
LithiumLithium may increase the serotonergic activities of Fluvoxamine.Approved
LobeglitazoneThe metabolism of Fluvoxamine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Lofepramine.Experimental
LomefloxacinThe metabolism of Lomefloxacin can be decreased when combined with Fluvoxamine.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Fluvoxamine.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Fluvoxamine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Fluvoxamine.Approved
LopinavirThe metabolism of Fluvoxamine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Loprazolam.Experimental
LoratadineThe metabolism of Loratadine can be decreased when combined with Fluvoxamine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluvoxamine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Fluvoxamine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Lormetazepam.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Fluvoxamine.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Fluvoxamine.Approved
LovastatinThe metabolism of Lovastatin can be decreased when combined with Fluvoxamine.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluvoxamine.Approved
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Fluvoxamine.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Fluvoxamine.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Fluvoxamine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Fluvoxamine.Illicit, Investigational, Withdrawn
MacitentanThe metabolism of Macitentan can be decreased when combined with Fluvoxamine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Vet Approved
MalathionThe metabolism of Malathion can be decreased when combined with Fluvoxamine.Approved, Investigational
ManidipineThe metabolism of Fluvoxamine can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe serum concentration of Mannitol can be increased when it is combined with Fluvoxamine.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Fluvoxamine.Approved
MaravirocThe metabolism of Maraviroc can be decreased when combined with Fluvoxamine.Approved, Investigational
MebanazineMebanazine may increase the serotonergic activities of Fluvoxamine.Withdrawn
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Fluvoxamine.Approved, Vet Approved
MebicarThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Mebicar.Experimental
MecaserminFluvoxamine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Fluvoxamine.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Fluvoxamine.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Fluvoxamine.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Fluvoxamine.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Fluvoxamine.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Melperone.Approved, Investigational
MenadioneThe metabolism of Menadione can be decreased when combined with Fluvoxamine.Approved, Nutraceutical
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Fluvoxamine.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Fluvoxamine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Meptazinol.Experimental
MequitazineThe metabolism of Mequitazine can be decreased when combined with Fluvoxamine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Fluvoxamine.Approved, Investigational
MestranolThe metabolism of Mestranol can be decreased when combined with Fluvoxamine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Fluvoxamine.Experimental
MetforminFluvoxamine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Fluvoxamine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Fluvoxamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Methapyrilene.Withdrawn
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Fluvoxamine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluvoxamine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Fluvoxamine.Approved
MethotrimeprazineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Fluvoxamine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Fluvoxamine.Approved, Investigational, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Fluvoxamine.Approved
MethyclothiazideFluvoxamine may increase the hyponatremic activities of Methyclothiazide.Approved
Methyl salicylateThe metabolism of Methyl salicylate can be decreased when combined with Fluvoxamine.Approved, Vet Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Methylecgonine.Experimental
Methylene blueFluvoxamine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Fluvoxamine.Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Fluvoxamine.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Fluvoxamine.Approved
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Fluvoxamine.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Fluvoxamine.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Fluvoxamine.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Fluvoxamine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluvoxamine.Approved, Investigational
MetolazoneFluvoxamine may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fluvoxamine.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Fluvoxamine.Approved
MetyrosineFluvoxamine may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Fluvoxamine.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Fluvoxamine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Fluvoxamine.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be decreased when combined with Fluvoxamine.Investigational, Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Fluvoxamine.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Fluvoxamine.Approved, Illicit
MidostaurinThe metabolism of Fluvoxamine can be decreased when combined with Midostaurin.Approved
MifepristoneThe metabolism of Mifepristone can be decreased when combined with Fluvoxamine.Approved, Investigational
MiglitolFluvoxamine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Milnacipran.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Fluvoxamine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Fluvoxamine.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Mirtazapine.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Fluvoxamine.Approved, Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Fluvoxamine.Approved
ModafinilThe metabolism of Modafinil can be decreased when combined with Fluvoxamine.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Molindone.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Fluvoxamine.Approved
MoperoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Fluvoxamine.Approved, Investigational, Withdrawn
MorphineThe metabolism of Morphine can be decreased when combined with Fluvoxamine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Mosapramine.Experimental
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Fluvoxamine.Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Fluvoxamine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Investigational
NabumetoneThe metabolism of Nabumetone can be decreased when combined with Fluvoxamine.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Fluvoxamine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluvoxamine.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Fluvoxamine.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Fluvoxamine.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Naratriptan.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Fluvoxamine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Fluvoxamine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Fluvoxamine.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Fluvoxamine.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Fluvoxamine.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Fluvoxamine.Approved
NialamideNialamide may increase the serotonergic activities of Fluvoxamine.Withdrawn
NicardipineThe metabolism of Nicardipine can be decreased when combined with Fluvoxamine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Fluvoxamine.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Fluvoxamine.Approved, Investigational, Vet Approved
NicomorphineNicomorphine may increase the serotonergic activities of Fluvoxamine.Experimental
NicotineThe metabolism of Nicotine can be decreased when combined with Fluvoxamine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Fluvoxamine.Approved
NilotinibThe metabolism of Nilotinib can be decreased when combined with Fluvoxamine.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Fluvoxamine.Approved
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Fluvoxamine.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Fluvoxamine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Fluvoxamine.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Fluvoxamine.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Fluvoxamine.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Fluvoxamine.Approved, Investigational
Nitric OxideThe metabolism of Nitric Oxide can be decreased when combined with Fluvoxamine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Fluvoxamine.Approved, Investigational, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fluvoxamine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Fluvoxamine.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Fluvoxamine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Norflurane.Investigational
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Fluvoxamine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Nortriptyline.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Fluvoxamine.Withdrawn
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Fluvoxamine.Investigational
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Fluvoxamine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Fluvoxamine.Approved
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Fluvoxamine.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Fluvoxamine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Fluvoxamine.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Fluvoxamine.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Fluvoxamine.Approved
OpipramolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Opium.Approved, Illicit
OrphenadrineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Fluvoxamine can be decreased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Fluvoxamine.Approved
OxaliplatinThe metabolism of Oxaliplatin can be decreased when combined with Fluvoxamine.Approved, Investigational
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Fluvoxamine.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Fluvoxamine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Oxethazaine.Approved, Investigational
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Fluvoxamine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Oxprenolol.Approved
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Fluvoxamine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Oxybuprocaine.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Fluvoxamine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Fluvoxamine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Oxypertine.Experimental
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Fluvoxamine.Approved, Vet Approved
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Fluvoxamine.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluvoxamine.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Fluvoxamine.Approved, Investigational
PanobinostatThe serum concentration of Fluvoxamine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Fluvoxamine.Approved
ParaldehydeFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Fluvoxamine.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Fluvoxamine.Approved
ParecoxibFluvoxamine may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Fluvoxamine.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Fluvoxamine.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Fluvoxamine.Approved
ParoxetineThe metabolism of Fluvoxamine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Fluvoxamine.Approved
Peginterferon alfa-2bThe serum concentration of Fluvoxamine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Penfluridol.Experimental
PentamidineThe metabolism of Pentamidine can be decreased when combined with Fluvoxamine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluvoxamine.Approved, Vet Approved
PentobarbitalThe metabolism of Pentobarbital can be decreased when combined with Fluvoxamine.Approved, Vet Approved
PentoxifyllineThe serum concentration of Pentoxifylline can be increased when it is combined with Fluvoxamine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Fluvoxamine.Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Fluvoxamine.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Fluvoxamine.Approved, Investigational
PermethrinThe metabolism of Permethrin can be decreased when combined with Fluvoxamine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Fluvoxamine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Fluvoxamine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Fluvoxamine.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Phenelzine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Fluvoxamine.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Phenibut.Experimental
PhenindioneFluvoxamine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Fluvoxamine.Withdrawn
PhenobarbitalThe metabolism of Phenobarbital can be decreased when combined with Fluvoxamine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Phenoperidine.Experimental
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Fluvoxamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Phenoxyethanol.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Fluvoxamine.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Fluvoxamine.Approved, Investigational
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Fluvoxamine.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Fluvoxamine.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Fluvoxamine.Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Fluvoxamine.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Fluvoxamine.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Fluvoxamine.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Fluvoxamine.Withdrawn
PindololThe metabolism of Pindolol can be decreased when combined with Fluvoxamine.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Fluvoxamine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Pipamperone.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Fluvoxamine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Fluvoxamine.Approved, Investigational
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Fluvoxamine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Piritramide.Investigational
PirlindolePirlindole may increase the serotonergic activities of Fluvoxamine.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Fluvoxamine.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Fluvoxamine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Fluvoxamine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Pizotifen.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Fluvoxamine.Approved
PolythiazideFluvoxamine may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Fluvoxamine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Fluvoxamine.Approved
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Fluvoxamine.Approved, Investigational, Vet Approved
PramipexoleFluvoxamine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideFluvoxamine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Pramocaine.Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Fluvoxamine.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Fluvoxamine.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Fluvoxamine.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Fluvoxamine.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Fluvoxamine.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Fluvoxamine.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Fluvoxamine.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Fluvoxamine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluvoxamine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Prilocaine.Approved
PrimaquineThe metabolism of Primaquine can be decreased when combined with Fluvoxamine.Approved
PrimidoneThe metabolism of Primidone can be decreased when combined with Fluvoxamine.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Fluvoxamine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Procarbazine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Fluvoxamine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Fluvoxamine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Fluvoxamine.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Fluvoxamine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Promethazine.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Fluvoxamine.Approved
PropanididThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Propericiazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Fluvoxamine.Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Fluvoxamine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Propoxycaine.Approved
Propoxyphene napsylateThe metabolism of Propoxyphene napsylate can be decreased when combined with Fluvoxamine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Fluvoxamine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Fluvoxamine.Approved
PSD502The risk or severity of adverse effects can be increased when Fluvoxamine is combined with PSD502.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Fluvoxamine.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Fluvoxamine.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Fluvoxamine.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Fluvoxamine.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Fluvoxamine.Approved, Investigational
QuinethazoneFluvoxamine may increase the hyponatremic activities of Quinethazone.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Fluvoxamine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Fluvoxamine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Quinisocaine.Experimental
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Fluvoxamine.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Raclopride.Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Fluvoxamine.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Fluvoxamine.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Fluvoxamine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Fluvoxamine.Approved, Investigational
RasagilineThe serum concentration of Rasagiline can be increased when it is combined with Fluvoxamine.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Fluvoxamine.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Fluvoxamine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluvoxamine.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Fluvoxamine.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Fluvoxamine.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Fluvoxamine.Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Fluvoxamine.Approved, Investigational
ResveratrolThe metabolism of Resveratrol can be decreased when combined with Fluvoxamine.Approved, Experimental, Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Fluvoxamine.Approved
RifabutinThe metabolism of Rifabutin can be decreased when combined with Fluvoxamine.Approved
RifampicinThe metabolism of Rifampicin can be decreased when combined with Fluvoxamine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Fluvoxamine.Approved, Investigational
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Fluvoxamine.Approved
RiluzoleThe metabolism of Riluzole can be decreased when combined with Fluvoxamine.Approved, Investigational
RimonabantThe metabolism of Rimonabant can be decreased when combined with Fluvoxamine.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Fluvoxamine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Fluvoxamine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ritanserin.Investigational
RitonavirThe metabolism of Ritonavir can be decreased when combined with Fluvoxamine.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Fluvoxamine.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Fluvoxamine.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Fluvoxamine.Investigational, Withdrawn
RoflumilastThe serum concentration of the active metabolites of Roflumilast can be increased when Roflumilast is used in combination with Fluvoxamine.Approved
RolapitantThe metabolism of Rolapitant can be decreased when combined with Fluvoxamine.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Fluvoxamine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Romifidine.Vet Approved
RopiniroleFluvoxamine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Fluvoxamine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Fluvoxamine.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Fluvoxamine.Approved
RotigotineFluvoxamine may increase the sedative activities of Rotigotine.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Fluvoxamine.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Fluvoxamine.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fluvoxamine.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Fluvoxamine.Approved
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Fluvoxamine.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Fluvoxamine.Approved
SafrazineSafrazine may increase the serotonergic activities of Fluvoxamine.Withdrawn
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Fluvoxamine.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Fluvoxamine.Approved
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Fluvoxamine.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Fluvoxamine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluvoxamine.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Fluvoxamine.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Fluvoxamine.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sepranolone.Investigational
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Fluvoxamine.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Fluvoxamine.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Fluvoxamine.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Fluvoxamine.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Fluvoxamine.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Sildenafil can be decreased when combined with Fluvoxamine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Fluvoxamine.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Fluvoxamine.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Fluvoxamine.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Fluvoxamine.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Fluvoxamine.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Fluvoxamine.Approved, Investigational, Withdrawn
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Fluvoxamine.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Fluvoxamine.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Fluvoxamine.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Fluvoxamine.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Fluvoxamine.Approved, Investigational
SparteineThe metabolism of Sparteine can be decreased when combined with Fluvoxamine.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Fluvoxamine.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Fluvoxamine.Approved
StiripentolThe metabolism of Fluvoxamine can be decreased when combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Fluvoxamine.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Fluvoxamine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Fluvoxamine.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Fluvoxamine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Fluvoxamine.Approved
SulfisoxazoleThe metabolism of Sulfisoxazole can be decreased when combined with Fluvoxamine.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sumatriptan.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Fluvoxamine.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Fluvoxamine.Approved, Withdrawn
SuvorexantFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Fluvoxamine.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Fluvoxamine.Approved
TacrineThe metabolism of Tacrine can be decreased when combined with Fluvoxamine.Investigational, Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Fluvoxamine.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Fluvoxamine.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Fluvoxamine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Fluvoxamine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Fluvoxamine.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Fluvoxamine.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Fluvoxamine.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Fluvoxamine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Fluvoxamine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Fluvoxamine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Fluvoxamine.Investigational, Withdrawn
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Fluvoxamine.Approved, Withdrawn
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Fluvoxamine.Approved
TemafloxacinThe metabolism of Temafloxacin can be decreased when combined with Fluvoxamine.Withdrawn
TemazepamThe metabolism of Temazepam can be decreased when combined with Fluvoxamine.Approved
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Fluvoxamine.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Fluvoxamine.Approved
Tenofovir disoproxilThe metabolism of Fluvoxamine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Fluvoxamine.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Fluvoxamine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Fluvoxamine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Fluvoxamine.Experimental
TeriflunomideThe serum concentration of Fluvoxamine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Fluvoxamine.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Fluvoxamine.Approved, Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Fluvoxamine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tetracaine.Approved, Vet Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Fluvoxamine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tetrodotoxin.Investigational
ThalidomideFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe metabolism of Theobromine can be decreased when combined with Fluvoxamine.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Fluvoxamine.Approved
ThiabendazoleThe metabolism of Thiabendazole can be decreased when combined with Fluvoxamine.Approved, Vet Approved
ThiamylalThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Fluvoxamine.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Fluvoxamine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Fluvoxamine.Approved, Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Fluvoxamine.Approved
ThiothixeneThe metabolism of Thiothixene can be decreased when combined with Fluvoxamine.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Fluvoxamine.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Fluvoxamine.Approved
TianeptineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tiapride.Approved, Investigational
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Fluvoxamine.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Fluvoxamine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tilidine.Experimental
TimololThe metabolism of Timolol can be decreased when combined with Fluvoxamine.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Fluvoxamine.Approved, Investigational
TioclomarolFluvoxamine may increase the anticoagulant activities of Tioclomarol.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Fluvoxamine.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Fluvoxamine.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Fluvoxamine.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Fluvoxamine.Approved, Investigational
TolazamideFluvoxamine may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Fluvoxamine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Fluvoxamine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Fluvoxamine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Fluvoxamine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Fluvoxamine.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Fluvoxamine.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Fluvoxamine.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Fluvoxamine.Approved, Investigational
TramadolFluvoxamine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Fluvoxamine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trazodone.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Fluvoxamine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Fluvoxamine.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Fluvoxamine.Approved, Vet Approved
TriamtereneThe metabolism of Triamterene can be decreased when combined with Fluvoxamine.Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Fluvoxamine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideFluvoxamine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trichloroethylene.Experimental
TrifluoperazineThe metabolism of Trifluoperazine can be decreased when combined with Fluvoxamine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluvoxamine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Fluvoxamine.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Fluvoxamine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Triprolidine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Fluvoxamine.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Fluvoxamine.Approved
TropisetronTropisetron may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Fluvoxamine.Approved, Experimental
UdenafilThe metabolism of Udenafil can be decreased when combined with Fluvoxamine.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Fluvoxamine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Fluvoxamine.Approved
VadimezanThe metabolism of Vadimezan can be decreased when combined with Fluvoxamine.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Fluvoxamine.Approved, Investigational
ValdecoxibFluvoxamine may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Fluvoxamine.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Fluvoxamine.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Fluvoxamine.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Fluvoxamine.Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Fluvoxamine.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Fluvoxamine.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Fluvoxamine.Approved
VemurafenibThe serum concentration of Fluvoxamine can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Fluvoxamine.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Fluvoxamine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Veralipride.Experimental
VerapamilThe metabolism of Verapamil can be decreased when combined with Fluvoxamine.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Fluvoxamine.Approved, Investigational
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Fluvoxamine.Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Vigabatrin.Approved
VilanterolThe metabolism of Vilanterol can be decreased when combined with Fluvoxamine.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Fluvoxamine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Fluvoxamine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Fluvoxamine.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Fluvoxamine.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Fluvoxamine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Fluvoxamine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Vinyl ether.Experimental
VismodegibThe metabolism of Vismodegib can be decreased when combined with Fluvoxamine.Approved
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Fluvoxamine.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Fluvoxamine.Approved
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Fluvoxamine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Fluvoxamine.Approved
XenonThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Xenon.Experimental
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Fluvoxamine.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Fluvoxamine can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Fluvoxamine.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Fluvoxamine.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Fluvoxamine.Approved, Illicit, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Fluvoxamine.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ziconotide.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Fluvoxamine.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Fluvoxamine.Approved, Investigational, Withdrawn
ZimelidineFluvoxamine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Fluvoxamine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Zolazepam.Vet Approved
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Fluvoxamine.Approved, Investigational
ZolpidemFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Fluvoxamine.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Fluvoxamine.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Fluvoxamine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Zotepine.Approved, Investigational
ZucapsaicinThe metabolism of Fluvoxamine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Fluvoxamine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid high doses of caffeine.
  • Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can significantly increase serum levels of this product.
  • Take without regard to meals.

References

Synthesis Reference

Welle, H.B.A. and Claassen, V.; U.S. Patent 4,085,225; April 18, 1978; assigned to U.S. Phillips Corp.

General References
  1. Dell'Osso B, Allen A, Hollander E: Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother. 2005 Dec;6(15):2727-40. [PubMed:16316311]
  2. Irons J: Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat. 2005 Dec;1(4):289-99. [PubMed:18568110]
External Links
KEGG Compound
C07571
PubChem Compound
3404
PubChem Substance
46507588
ChemSpider
4481878
BindingDB
50028091
ChEBI
5138
ChEMBL
CHEMBL814
Therapeutic Targets Database
DNC000897
PharmGKB
PA449690
HET
FVX
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Fluvoxamine
ATC Codes
N06AB08 — Fluvoxamine
AHFS Codes
  • 28:16.04.20 — Selective-serotonin Reuptake Inhibitors
PDB Entries
4enh / 4mm9 / 6awp
FDA label
Download (633 KB)
MSDS
Download (48.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHealthy Volunteers / Pharmacology, Clinical1
1CompletedBasic ScienceDepressive State1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedOtherHealthy Volunteers / Pharmacokinetics of Quetiapine1
1CompletedPreventionHealthy Volunteers1
1CompletedTreatmentAdvanced Solid Tumors, Excluding Breast Cancer1
1CompletedTreatmentDrug Interaction of Clopidogrel1
1CompletedTreatmentDrug Interactions Between Clopidogrel and Serotonin Reuptake Inhibitors1
1CompletedTreatmentHealthy Volunteers1
1Not Yet RecruitingTreatmentHealthy Volunteers1
3CompletedTreatmentAnxiety Disorders / Generalized Anxiety Disorder (GAD) / Obsessive-Compulsive Disorder (OCD) / Separation Anxiety / Social Phobia1
3CompletedTreatmentAutism, Early Infantile1
3CompletedTreatmentObsessive Compulsive Disorder (OCD)1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
4CompletedTreatmentMajor Depressive Disorder (MDD)2
4CompletedTreatmentRecurrent Depressive Disorder1
4CompletedTreatmentSchizophrenic Disorders1
4RecruitingNot AvailableDepressive Disorders / Lactation1
4RecruitingTreatmentAnxiety Disorders / Obsessive-Compulsive Disorder (OCD) / Psychiatric Disorder NOS1
4RecruitingTreatmentDepressive Disorders1
4TerminatedTreatmentObsessive Compulsive Disorder (OCD)1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)2
4Unknown StatusTreatmentObsessive Compulsive Disorder (OCD)1
Not AvailableCompletedNot AvailableAcute Kidney Injury (AKI) / Depressive State1
Not AvailableCompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD) / Generalized Anxiety Disorder (GAD) / Separation Anxiety / Social Phobia1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableObsessive-Compulsive Disorder (OCD)1
Not AvailableRecruitingTreatmentAlcohol-Related Disorders / Brain Injury / Chronic Diseases / Depressive State / Mild Cognitive Impairment (MCI) / Pain / Posttraumatic Stress Disorders / Quality of Life / Substance-Related Disorders / Suicidal Ideation / Wounds and Injuries1
Not AvailableRecruitingTreatmentObsessive-Compulsive Disorder (OCD)2
Not AvailableUnknown StatusTreatmentDepressive State1
Not AvailableUnknown StatusTreatmentSCHIZOPHRENIA 1 (Disorder)1
Not AvailableUnknown StatusTreatmentSchizophrenic Disorders1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1

Pharmacoeconomics

Manufacturers
  • Jazz pharmaceuticals
  • Actavis elizabeth llc
  • Apotex inc
  • Barr laboratories inc
  • Caraco pharmaceutical laboratories ltd
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Synthon pharmaceuticals ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Ani pharmaceuticals inc
  • Solvay pharmaceuticals
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral50 mg
TabletOral100.0 mg
TabletOral50.0 mg
TabletOral100 mg/1
TabletOral25 mg/1
TabletOral50 mg/1
Tablet, coatedOral100 mg/1
Tablet, coatedOral25 mg/1
Tablet, coatedOral50 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
Capsule, extended releaseOral100 mg/1
Capsule, extended releaseOral150 mg/1
Prices
Unit descriptionCostUnit
Luvox CR 150 mg 24 Hour Capsule6.34USD capsule
Luvox cr 150 mg capsule6.24USD capsule
Luvox CR 100 mg 24 Hour Capsule6.05USD capsule
Luvox cr 100 mg capsule5.82USD capsule
Fluvoxamine maleate 100 mg tablet2.69USD tablet
Fluvoxamine mal 100 mg tablet2.63USD tablet
Fluvoxamine maleate 50 mg tablet2.61USD tablet
Fluvoxamine maleate 25 mg tablet2.34USD tablet
Luvox 100 mg Tablet1.7USD tablet
Luvox 50 mg Tablet0.95USD tablet
Apo-Fluvoxamine 100 mg Tablet0.93USD tablet
Co Fluvoxamine 100 mg Tablet0.93USD tablet
Novo-Fluvoxamine 100 mg Tablet0.93USD tablet
Nu-Fluvoxamine 100 mg Tablet0.93USD tablet
Pms-Fluvoxamine 100 mg Tablet0.93USD tablet
Ratio-Fluvoxamine 100 mg Tablet0.93USD tablet
Sandoz Fluvoxamine 100 mg Tablet0.93USD tablet
Apo-Fluvoxamine 50 mg Tablet0.52USD tablet
Co Fluvoxamine 50 mg Tablet0.52USD tablet
Novo-Fluvoxamine 50 mg Tablet0.52USD tablet
Nu-Fluvoxamine 50 mg Tablet0.52USD tablet
Pms-Fluvoxamine 50 mg Tablet0.52USD tablet
Ratio-Fluvoxamine 50 mg Tablet0.52USD tablet
Sandoz Fluvoxamine 50 mg Tablet0.52USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7465462No2000-05-102020-05-10Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)120-121.5 °CWelle, H.B.A. and Claassen, V.; U.S. Patent 4,085,225; April 18, 1978; assigned to U.S. Phillips Corp.
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00734 mg/mLALOGPS
logP2.89ALOGPS
logP2.8ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)9.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area56.84 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity79.2 m3·mol-1ChemAxon
Polarizability32.44 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9775
Caco-2 permeable-0.5149
P-glycoprotein substrateSubstrate0.6079
P-glycoprotein inhibitor IInhibitor0.7883
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.5325
CYP450 2C9 substrateNon-substrate0.8595
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6723
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8481
Ames testNon AMES toxic0.5
CarcinogenicityNon-carcinogens0.637
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6997 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8427
hERG inhibition (predictor II)Inhibitor0.7995
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-066r-0179000000-511765bf69bd5c60c543

Taxonomy

Description
This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Trifluoromethylbenzenes
Direct Parent
Trifluoromethylbenzenes
Alternative Parents
Dialkyl ethers / Organopnictogen compounds / Organofluorides / Monoalkylamines / Hydrocarbon derivatives / Alkyl fluorides
Substituents
Trifluoromethylbenzene / Dialkyl ether / Ether / Alkyl fluoride / Organopnictogen compound / Hydrocarbon derivative / Primary amine / Organooxygen compound / Organonitrogen compound / Organofluoride
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Kakiuchi T, Tsukada H, Fukumoto D, Nishiyama S: Effects of aging on serotonin transporter availability and its response to fluvoxamine in the living brain: PET study with [(11)C](+)McN5652 and [(11)C](-)McN5652 in conscious monkeys. Synapse. 2001 Jun 1;40(3):170-9. [PubMed:11304754]
  2. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):383-6. [PubMed:11817517]
  3. Miolo G, Caffieri S, Levorato L, Imbesi M, Giusti P, Uz T, Manev R, Manev H: Photoisomerization of fluvoxamine generates an isomer that has reduced activity on the 5-hydroxytryptamine transporter and does not affect cell proliferation. Eur J Pharmacol. 2002 Aug 30;450(3):223-9. [PubMed:12208313]
  4. Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, Ikoma Y, Okubo Y: High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry. 2003 Apr;60(4):386-91. [PubMed:12695316]
  5. Inoue K: [Analysis and its application for prevention of side-effects of drugs and for evaluation of drug responsiveness]. Yakugaku Zasshi. 2004 Jun;124(6):293-9. [PubMed:15170064]
  6. McMahon LR, Cunningham KA: Role of 5-HT(2a) and 5-HT(2B/2C) receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors. Neuropsychopharmacology. 2001 Mar;24(3):319-29. [PubMed:11166521]
  7. Millan MJ, Veiga S, Girardon S, Brocco M: Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes. Psychopharmacology (Berl). 2003 Aug;168(4):397-409. Epub 2003 Apr 30. [PubMed:12721776]
  8. Dell'Osso B, Allen A, Hollander E: Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother. 2005 Dec;6(15):2727-40. [PubMed:16316311]
  9. Irons J: Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat. 2005 Dec;1(4):289-99. [PubMed:18568110]
  10. Williams K, Wheeler DM, Silove N, Hazell P: Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2010 Aug 4;(8):CD004677. doi: 10.1002/14651858.CD004677.pub2. [PubMed:20687077]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Friemel A, Zunkler BJ: Interactions at human ether-a-go-go-related gene channels. Toxicol Sci. 2010 Apr;114(2):346-55. doi: 10.1093/toxsci/kfq011. Epub 2010 Jan 13. [PubMed:20071423]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657]
  2. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Rasmussen BB, Nielsen TL, Brosen K: Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol. 1998 Dec;83(6):240-5. [PubMed:9868741]
  2. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657]
  3. Brosen K: Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet. 1995;29 Suppl 1:20-5. [PubMed:8846619]
  4. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628]
  5. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624]
  6. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  7. Yasui-Furukori N, Inoue Y, Kaneko S, Otani K: Determination of fluvoxamine and its metabolite fluvoxamino acid by liquid-liquid extraction and column-switching high-performance liquid chromatography. J Pharm Biomed Anal. 2005 Feb 7;37(1):121-5. [PubMed:15664751]
  8. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657]
  2. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
8. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]
  2. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369]

Drug created on June 13, 2005 07:24 / Updated on November 14, 2017 08:00